Clinical Trial Update: Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma [Phase 1, Phase 2]

View source ↗

Summary

Selumetinib is being studied in pediatric patients with recurrent or refractory low-grade glioma across Phase 1 and Phase 2 trials; the study status is ACTIVE_N…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma
• Neurofibromatosis Type
• Optic Pathway Glioma
• Pilocytic Astrocytoma

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING